Frankfurt
10.04.26 | 09:55
5,200 Euro
-0,95 % -0,050
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,200 | 5,550 | 11.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | ASCENTAGE-B (06855): CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 2 | HKEx | ||
| 27.03. | Oppenheimer reiterates Ascentage Pharma stock rating on China growth | 1 | Investing.com | ||
| 27.03. | Wachstum in China: Oppenheimer bestätigt "Outperform"-Rating für Ascentage Pharma | - | Investing.com Deutsch | ||
| 26.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.03. | Ascentage Pharma Group International GAAP EPS of $0.50 beats by $1.66 | 1 | Seeking Alpha | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 26.03. | Ascentage Pharma - B Last Year's Loss Expanded to RMB1.243 Billion | 1 | AASTOCKS | ||
| 26.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates | 177 | GlobeNewswire (Europe) | Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3... ► Artikel lesen | |
| 25.03. | ASCENTAGE-B (06855): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025; AND CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE | 1 | HKEx | ||
| 18.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 18.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 18.03. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT DATA FROM FOUR PRECLINICAL STUDIES IN ITS INNOVATIVE PIPELINE AT AMERICAN ASSOCIATION ... | 1 | HKEx | ||
| 13.03. | ASCENTAGE-B (06855): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 11.03. | BTIG initiates Ascentage Pharma stock coverage with buy rating | 1 | Investing.com | ||
| 11.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.03. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 | 2 | GlobeNewswire (USA) | ||
| 23.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.02. | Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target | 2 | Insider Monkey | ||
| 06.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.02. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 | 319 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company... ► Artikel lesen | |
| 15.01. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,524 | +1,74 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,950 | -0,86 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| EDITAS MEDICINE | 2,430 | -3,19 % | Editas Medicine, Inc. - 8-K, Current Report | ||
| SAREPTA THERAPEUTICS | 18,100 | +0,11 % | Johnson Fistel, PLLP: Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty | San Diego, California--(Newsfile Corp. - January 12, 2026) - Shareholder rights law firm Johnson Fistel, PLLP is investigating potential shareholder derivative claims on behalf of Sarepta Therapeutics... ► Artikel lesen | |
| BASILEA | 58,60 | -0,34 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea erhält zusätzliche USD 6 Mio. von CARB-X für die klinische Entwicklung des Antibiotikums BAL2420 | Zusage der finanziellen Förderung nach erfolgreichem Abschluss präklinischer Studien und Erhalt der Genehmigung zur Durchführung klinischer Studien Zusätzliche USD 6 Mio. für die erstmalige Erprobung... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 8,819 | +0,40 % | Telix Pharmaceuticals Q1 Group Revenue Rises; Stock Up | CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) reported that its group revenue for the first quarter of fiscal year 2016 increased about 24% to US$230 million, from US$186 million... ► Artikel lesen | |
| REPLIGEN | 102,04 | 0,00 % | Repligen Corporation: Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Fourth quarter revenue of $198 million, a year-over-year increase of 18% as reported, 14% organic with continued momentum in orders in the quarterFull year 2025 revenue of $738 million, a year-over-year... ► Artikel lesen | |
| UNIQURE | 13,380 | +1,98 % | uniQure Inc.: uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease | LEXINGTON, Mass. and AMSTERDAM, March 02, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs... ► Artikel lesen | |
| CODEXIS | 1,989 | +3,92 % | Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform | REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 50,50 | -0,98 % | Stifel reiterates Oruka Therapeutics stock rating ahead of trial data | ||
| MACROGENICS | 3,000 | -2,60 % | Weekly Buzz: MacroGenics Resumes LINNET; GSK Wins China Nod; FDA Okays Waters Corporation; Neurocrine Biosciences Snaps Up Soleno Therapeutics | THOUSAND OAKS (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations... ► Artikel lesen | |
| OMEROS | 9,900 | +1,02 % | Omeros Corporation: Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment | Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22,... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,280 | -0,09 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 16,465 | -0,36 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,080 | +6,94 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026 | MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets
MUC16 is highly and stably expressed in the most... ► Artikel lesen |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,050 (-0,95 %) liegt der Kurs bei 5,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.